WEBULL
WebtradeDownload

Is Vaxcyte (PCVX) Undervalued Following Positive OPUS 1 Phase 3 Data?

Simply Wall St · 2d ago

Vaxcyte (PCVX) has drawn fresh attention after reporting a third quarter net loss of US$297.06 million, while at the same time highlighting positive topline Phase 3 OPUS-1 data for its VAX-31 pneumococcal vaccine candidate.

That positive OPUS-1 update arrived alongside a sharp move in the share price, with Vaxcyte up 8.01% on the day and 6.87% over the past week. This comes even though the 30-day share price return is down 11.03%, while longer term momentum remains strong with a 41.37% year to date share price return and a 62.90% total shareholder return over the past year.

Scan how Vaxcyte's OPUS-1 success compares with other potential breakout biotech opportunities by reviewing the hand picked 38 healthcare AI stocks in this space.

After Vaxcyte's sharp run on OPUS-1 data, the key tension is simple. Has the recent rally already captured most of the opportunity, or does the current valuation still leave meaningful upside on the table?

Most Popular Narrative: 44% Undervalued

Analysts following Vaxcyte see a wide gap between the narrative fair value of $117.30 and the last close at $65.68. They are tying that gap squarely to how OPUS-1 reshapes expectations for VAX-31 and the wider pneumococcal franchise.

Vaxcyte is a vaccine company focused on developing broader-coverage pneumococcal and Group A Strep vaccines for adult and pediatric use.

Multiple ongoing late stage VAX-31 adult trials and the planned BLA package are aligned with existing FDA frameworks for pneumococcal vaccines. If successful, these programs could support future product approvals and create a path to commercial revenue.

See why 2 investors see Vaxcyte as 44% undervalued.

Result: Fair Value of $117.30 (UNDERVALUED)

Still, the bullish Vaxcyte story leans heavily on VAX-31 delivering across multiple Phase 3 studies, while rising R&D and manufacturing spend could strain that US$3.0b cash runway faster than planned.

Find out about the key risks to this Vaxcyte narrative.

Next Steps

Sentiment on Vaxcyte is split, with enthusiasm for OPUS-1 sitting alongside concern about execution risk and cash burn. Act quickly and weigh both sides by checking the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Vaxcyte?

If Vaxcyte has sharpened your focus on opportunity and risk, do not stop here. Broaden your watchlist using targeted screens that surface clear, differentiated ideas.